AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04335760 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Modified Bruce protocol on treadmill
Description: Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available.
Study NCT01723371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
Study NCT01664260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
Study NCT01664260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
Study NCT03495167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101
Description: SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
Study NCT02016027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carica folia
Study NCT02395393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alveoflex Confocal MiniprobeTM
Description: -Alveolar imaging
Study NCT01226160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative non-posturing group
Description: avoid a face-up position only for 10 days after surgery
Study NCT00954759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Study NCT00954759 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Visit without active treatment
Description: The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
Study NCT03727074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Cream
Description: topical cream twice a day
Study NCT03727074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efudex®
Description: topical cream twice a day
Study NCT03727074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical cream twice a day
Study NCT00842673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 30 mg; administered once/day
Study NCT00842673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 90 mg; administered once/day
Study NCT00842673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 180 mg; administered once/day
Study NCT00842673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match ST101 tablets
Study NCT02783924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vitamin D preparation
Study NCT02954614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active play in after school programs (ASP)
Description: * A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~* A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period
Study NCT02783924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03623503 — intervention group
Intervention type: OTHER
Intervention: Observational study
Study NCT03740035 — intervention group
Intervention type: DEVICE
Intervention: eHealth for Sedentary Behavior
Description: Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
Study NCT01023815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Study NCT02316171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: CAVATAK is a purified preparation of CVA21
Study NCT02316171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Chemotherapy
Study NCT00799435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
Study NCT04354324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine
Description: The test group: low dosage (30mci). The control group: high dosage (100mci).
Study NCT04354324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioiodine
Description: The test group: low dosage (30mci). The control group: high dosage (100mci).
Study NCT00479713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
Study NCT00479713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator : rosuvastatin calcium
Description: rosuvastatin 10mg. The treatment duration will be 6 weeks.
Study NCT00479713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (unspecified)
Description: rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
Study NCT00479713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
Study NCT03216408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox
Study NCT03216408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Study NCT02872246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT02872246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT05332847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POC-US
Description: Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
Study NCT04503265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXI-5001:Dose Escalation Phase I
Description: Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Study NCT04503265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXI-5001:Dose Expansion Phase II
Description: Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Study NCT00191334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
Study NCT00191334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
Study NCT02173106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid & Cyclosporin
Description: oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
Study NCT02747810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NewTENS Design
Description: This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
Study NCT04466852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telemedicine-guided consultation
Description: Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
Study NCT06725251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Dyads will take part in a portrait-making project utilizing a collage approach. Each participant (i.e. dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself. Participants will be provided with a sample portrait as well as bins of materials. \]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
Study NCT06726317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The early palliative care intervention package was developed following the guidelines provided by the UK Medical Research Council for the development of complex interventions. The early palliative care intervention for patients with oral cancer had six components: 1) providing information, 2) addressing acute and functional issues, 3) nutritional care, 4) psychological support, 5) mindfulness therapy, and 6) coordination of the financial allowance. The package was formulated by triangulating literature review findings and several independent studies: a case-control study; in-depth interviews with experts in the field of oncology and palliative care in Sri Lanka; key-informant interviews with patients with oral cancer and their caregivers; and an observation study at the National Cancer Institute Sri Lanka- Apeksha Hospital). The intervention package was finalized through a
Study NCT03288571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
Study NCT03229083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carevive software
Description: In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
Study NCT01023815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Study NCT01023815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Study NCT01023815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Study NCT01023815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison (continuous steroids)
Description: continuous steroids
Study NCT01023815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednison (continuous steroids)
Description: continuous steroids
Study NCT00762073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: oral suspension
Study NCT00762073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral suspension matching budesonide
Study NCT04383652 — intervention group
Intervention type: OTHER
Intervention: Biological sample and clinical data collection
Description: Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
Study NCT00209235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive and psychosocial testing
Description: Neurocognitive and psychosocial testing
Study NCT04514224 — intervention group
Intervention type: OTHER
Intervention: Gabby implementation
Description: Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
Study NCT04514224 — intervention group
Intervention type: OTHER
Intervention: Evaluate the Gabby implementation
Description: Assess implementation outcomes using the Proctor Implementation Outcomes Framework
Study NCT04272411 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SCS stimulation
Description: Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
Study NCT04272411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonic SCS stimulation
Description: Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
Study NCT04272411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Burst SCS Stimulation
Description: Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
Study NCT02801149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wrist Magnetic Resonance Imaging (MRI)
Description: Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
Study NCT03442894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy Treatment
Description: All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
Study NCT03442894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy Treatment
Description: All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
Study NCT03442894 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Physical Therapy Treatment
Description: All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
Study NCT03442894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
Study NCT03442894 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.